期刊文献+

血浆置换在重症肌无力患者围术期的应用及疗效 被引量:5

Application and curative effect of plasma exchange in myasthenia gravis patients with thymectomy
下载PDF
导出
摘要 目的:探讨血浆置换在重症肌无力病人胸腺切除术围术期的应用,评价其疗效。方法:回顾性分析我院胸外科胸腺切除术治疗的50例重症肌无力病人的临床资料,所有患者手术前后口服免疫抑制剂、胆碱酯酶抑制剂;其中23例(A组)围术期进行血浆置换,另27例(B组)未进行血浆置换。ELISA法测定两组患者外周血乙酰胆碱受体抗体(acetylcholine receptor antibodies,AChRab)的浓度;比较术后外周血AChRab、临床记分、呼吸辅助时间、肌无力危象发生的差异。结果:A组患者术后AChRab浓度明显下降,且术后1d和1周时A组患者AChRab浓度较B组明显下降(P<0.05),术后1月时两组间差异无统计学意义(P>0.05)。A组患者术后呼吸辅助时间、肌无力危象的发生、术后1周时临床记分较B组差异均有统计学意义(均P<0.05)。结论:血浆置换配合胸腺切除术治疗可明显提高重症肌无力患者近期疗效,是一种安全有效的治疗方法。 Objective To explore the application of plasma exchange in myasthenia gravis(MG)patients with thymectomy,and to evaluate its curative effects.Methods The clinical data of 50 patients with thymectomy were analyzed retrospectively,and the patients were divided into Group A(23 cases,undergoing thymectomy and plasma exchange)and Group B(27 cases,undergoing thymectomy).The difference of serum concentration of AChRab was examined by ELISA,and the time of auxiliary breath,crisis of myasthenia and clinical evaluation in the 2 groups were compared.Results Serum concentration of AChRab in Group A descended obviously after the plasma exchange.One day and one week after the operation,the AChRab concentration in Group A was obviously lower than that in Group B,but there was no difference one month after the operation.One week after the operation,the time of auxiliary breath,crisis of myasthenia and clinical evaluation in Group A were less than those in Group B.Conclusion Plasma exchange together with thymectomy can improve the temporary curative effects in patients with MG.It is safe and effective for MG.
出处 《中南大学学报(医学版)》 CAS CSCD 北大核心 2007年第6期1089-1092,共4页 Journal of Central South University :Medical Science
关键词 血浆置换 胸腺切除 重症肌无力 plasma exchange thymectomy myasthenia gravis
  • 相关文献

参考文献7

二级参考文献17

  • 1肖波.重症肌无力发病机制的研究进展[J].中华神经科杂志,2005,38(4):217-219. 被引量:4
  • 2王秀云,许贤豪,孙宏,韩雄,张华,国红.重症肌无力病人的临床绝对评分法和相对评分法[J].中华神经科杂志,1997,30(2):87-90. 被引量:241
  • 3Carandina Maffeis R,Nucci A,Marques JF Jr,et al.Plasmapheresis in the treatment of myasthenia gravis:retrospective study of 26 patients[J].Arq Neurop Siquiatr,2004,62(2B):391
  • 4Vincent A,McConville J,Farrugia ME,et al.Antibodies in myasthenia gravis and related disorders[J].Ann N Y Acad Sci,2003,998:324
  • 5Vandiedonck C,Beaurain G,Giraud M,et al.Pleiotropic effects of the 81 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia[J].Proc.Natl Acad Sci USA,2004,101:15464
  • 6Aruna BV,Sela M,Mozes E.Down-regulation of T cell responses to AChR and reversal of EAMG manifestations in mice by a dual altered peptide ligand via induction of CD4(+) CD25(+)regulatory cells[J].J Neuroimmunol.2006,4:73
  • 7Christensen PB,Jensen TS,Tsiropoulos I,et al.Mortality and survival in myast henia gravis:a Danish population based study.J Neurol Neurosurg Psychiatry,1998;64:78~83
  • 8Wylam ME,Anderson PM,Kuntz NL,et al.Successful treatment of refractory myasthenia gravis using rituximab:a pediatric case report[J].J Pediatr,2003,143(5):674-7.
  • 9Pinching AJ,Peters DK,Newsom-davis J.Remission of myasthenia gravis following plasma exchange[J].Lancet,1976,25(2):1373-6.
  • 10Vincent A,Leite MI.Neuromuscular junction autoimmune disease:muscle specific kinase antibodies and treatments for myasthenia gravis[J].Curr Opin Neurol,2005,18(5):519-25.

共引文献47

同被引文献74

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部